Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02851485 | Bioavailability Study With GLPG1972 | PHASE1 | COMPLETED | 12 | — | — | Jul 1, 2016 | Aug 1, 2016 | Oct 4, 2016 | 1 | Netherlands |
To study the pharmacokinetics of 600 mg GLPG1972 administered as oral liquid solution or as oral tablet after overnight fasting or administered as oral tablet after a high-fat high calorie breakfast
To study the pharmacokinetics of 600 mg GLPG1972 administered as oral liquid solution or as oral tablet after overnight fasting or administered as oral tablet after a high-fat high calorie breakfast
To study the pharmacokinetics of 600 mg GLPG1972 administered as oral liquid solution or as oral tablet after overnight fasting or administered as oral tablet after a high-fat high calorie breakfast
To study the pharmacokinetics of 600 mg GLPG1972 administered as oral liquid solution or as oral tablet after overnight fasting or administered as oral tablet after a high-fat high calorie breakfast
To study the pharmacokinetics of 600 mg GLPG1972 administered as oral liquid solution or as oral tablet after overnight fasting or administered as oral tablet after a high-fat high calorie breakfast
To evaluate safety and tolerability of single oral doses of GLPG1972
To evaluate safety and tolerability of single oral doses of GLPG1972
To evaluate safety and tolerability of single oral doses of GLPG1972
To evaluate safety and tolerability of single oral doses of GLPG1972
To evaluate safety and tolerability of single oral doses of GLPG1972
| Arm | Type | Description |
|---|---|---|
| GLPG1972 600 mg oral solution fasted | EXPERIMENTAL | 600 mg GLPG1972 administered as oral solution after overnight fasting |
| GLPG1972 600 mg oral tablet fasted | EXPERIMENTAL | 600 mg GLPG1972 administered as oral tablet after overnight fasting |
| GLPG1972 600 mg oral tablet fed | EXPERIMENTAL | 600 mg GLPG1972 administered as oral tablet after a high-fat high-calorie breakfast |
| Name | Type | Description |
|---|---|---|
| GLPG1972 600 mg oral solution fasted | DRUG | dosing after overnight fasting |
| GLPG1972 600 mg oral tablet fasted | DRUG | dosing after overnight fasting |
| GLPG1972 600 mg oral tablet fed | DRUG | dosing after high-fat high-calorie breakfast |
Inclusion Criteria: 1. Male between 18 and 50 years of age, inclusive, on the day of signing the informed consent form (ICF). 2. A body mass index (BMI) between 18-30 kg/m², inclusive, with a weight of at least 50 kg. 3. Judged by the investigator to be in good health based upon the results of a me...